Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 3
1975 2
1976 2
1983 2
1985 3
1986 1
1987 1
1990 1
1992 2
1993 1
1994 4
1995 6
1996 3
1997 4
1998 5
1999 9
2000 17
2001 19
2002 35
2003 21
2004 39
2005 37
2006 47
2007 45
2008 40
2009 30
2010 36
2011 60
2012 61
2013 64
2014 62
2015 68
2016 53
2017 47
2018 68
2019 54
2020 70
2021 57
2022 55
2023 60
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

1,102 results

Results by year

Filters applied: . Clear all
Page 1
A novel era of cancer/testis antigen in cancer immunotherapy.
Meng X, Sun X, Liu Z, He Y. Meng X, et al. Int Immunopharmacol. 2021 Sep;98:107889. doi: 10.1016/j.intimp.2021.107889. Epub 2021 Jun 24. Int Immunopharmacol. 2021. PMID: 34174699 Free article. Review.
Tumor antigens include tumor-specific antigens and tumor-associated antigens, and they function as targets for immunotherapy, such as cancer vaccines and autologous T cells. Cancer/testis antigens (CTAs), which is a group of …
Tumor antigens include tumor-specific antigens and tumor-associated antigens, and they function as targets for immun
Progress and challenges of immunotherapy in triple-negative breast cancer.
Zhu Y, Zhu X, Tang C, Guan X, Zhang W. Zhu Y, et al. Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188593. doi: 10.1016/j.bbcan.2021.188593. Epub 2021 Jul 17. Biochim Biophys Acta Rev Cancer. 2021. PMID: 34280474 Review.
Triple-negative breast cancer (TNBC), a subtype of breast cancer, is defined as lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) expression. ...Following the development of immune checkpoint inhibition ( …
Triple-negative breast cancer (TNBC), a subtype of breast cancer, is defined as lacking estrogen receptor (ER), progesterone r …
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J. Thomas R, et al. Front Immunol. 2018 May 1;9:947. doi: 10.3389/fimmu.2018.00947. eCollection 2018. Front Immunol. 2018. PMID: 29770138 Free PMC article. Review.
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. ...Cancer treatment has been revolutionized over the last few decades with immunotherapy e …
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expressi …
Leveraging epigenetics to enhance the efficacy of cancer-testis antigen: a potential candidate for immunotherapy.
Gupta R, Jit BP, Kumar S, Mittan S, Tanwer P, Ray MD, Mathur S, Perumal V, Kumar L, Rath GK, Sharma A. Gupta R, et al. Epigenomics. 2022 Jul;14(14):865-886. doi: 10.2217/epi-2021-0479. Epub 2022 Jul 25. Epigenomics. 2022. PMID: 35872653 Review.
Inherent immunogenicity potential, oncogenic function and expression of cancer-testis/germline antigen (CTA) in ovarian cancer render them a potential candidate for immunotherapy. ...In addition to radiotherapy, chemotherapy, hormonal therapy, a …
Inherent immunogenicity potential, oncogenic function and expression of cancer-testis/germline antigen (CTA) in ovarian …
Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy.
Raza A, Merhi M, Inchakalody VP, Krishnankutty R, Relecom A, Uddin S, Dermime S. Raza A, et al. J Transl Med. 2020 Mar 27;18(1):140. doi: 10.1186/s12967-020-02306-y. J Transl Med. 2020. PMID: 32220256 Free PMC article. Review.
Antigenic profiling of cancer tissues and determination of any pre-existing immune responses to cancer antigens may help predict responses to immune intervention in cancer. NY-ESO-1, a cancer testis antigen is the most immun
Antigenic profiling of cancer tissues and determination of any pre-existing immune responses to cancer antigens
Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
Liu X, Xu Y, Xiong W, Yin B, Huang Y, Chu J, Xing C, Qian C, Du Y, Duan T, Wang HY, Zhang N, Yu JS, An Z, Wang R. Liu X, et al. J Immunother Cancer. 2022 Mar;10(3):e004035. doi: 10.1136/jitc-2021-004035. J Immunother Cancer. 2022. PMID: 35338087 Free PMC article.
To mimic the feature of T-cell receptor (TCR) that recognizes the complex of major histocompatibility class I and peptide on the cell surface derived from the processed intracellular antigen, we used NY-ESO-1, a cancer-testis antigen, to develop a TCR- …
To mimic the feature of T-cell receptor (TCR) that recognizes the complex of major histocompatibility class I and peptide on the cell surfac …
Immunotherapy in soft-tissue sarcoma.
Ayodele O, Razak ARA. Ayodele O, et al. Curr Oncol. 2020 Feb;27(Suppl 1):17-23. doi: 10.3747/co.27.5407. Epub 2020 Feb 1. Curr Oncol. 2020. PMID: 32174754 Free PMC article. Review.
In the advanced setting, the role of systemic therapies is modest and is associated with poor survival. With the discovery of immunotherapies in other tumour types such as melanoma and lung cancer, interest has been renewed in exploring immunotherapy in sts. …
In the advanced setting, the role of systemic therapies is modest and is associated with poor survival. With the discovery of immunothera
The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer.
Xu Y, Zou R, Wang J, Wang ZW, Zhu X. Xu Y, et al. Cell Prolif. 2020 Mar;53(3):e12770. doi: 10.1111/cpr.12770. Epub 2020 Feb 5. Cell Prolif. 2020. PMID: 32022332 Free PMC article. Review.
Preferentially expressed antigen in melanoma (PRAME), which belongs to the cancer/testis antigen (CTA) gene family, plays a pivotal role in multiple cellular processes and immunotherapy response in human cancers. ...Therefore, the modulation of …
Preferentially expressed antigen in melanoma (PRAME), which belongs to the cancer/testis antigen (CTA) gene fami …
NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis.
Smith SM, Iwenofu OH. Smith SM, et al. Chin Clin Oncol. 2018 Aug;7(4):44. doi: 10.21037/cco.2018.08.11. Chin Clin Oncol. 2018. PMID: 30173534 Free article. Review.
There is therefore an urgent need for development of better and more efficacious targeted therapies. Cancer testis antigens (CTAs) are a family of proteins in which aberrant gene-activation and subsequent high level mRNA expression, are restricted to testi
There is therefore an urgent need for development of better and more efficacious targeted therapies. Cancer testis antigens
Epigenetic therapy in immune-oncology.
Jones PA, Ohtani H, Chakravarthy A, De Carvalho DD. Jones PA, et al. Nat Rev Cancer. 2019 Mar;19(3):151-161. doi: 10.1038/s41568-019-0109-9. Nat Rev Cancer. 2019. PMID: 30723290 Review.
In addition to their abilities to reactivate genes, including tumour suppressors, that have acquired DNA methylation during carcinogenesis, they induce the expression of thousands of transposable elements including endogenous retroviruses and latent cancer testis
In addition to their abilities to reactivate genes, including tumour suppressors, that have acquired DNA methylation during carcinogenesis, …
1,102 results